Case report: Cerebellar atrophy associated with phenytoin intoxication in a town in the Amazon region
DOI:
https://doi.org/10.33448/rsd-v12i3.40402Keywords:
Phenytoin; Cerebellar atrophy; Epilepsy.Abstract
Cerebellar ataxia is one of the classic symptoms of cerebellar atrophy, also considered one of the main lesions that affect motor coordination, being irreversible and interfering in the performance of movements, which are uncertain, unsafe, uncoordinated and imprecise, thus weakening the motor frame of the patient. This cerebellar injury can be caused by high doses associated with the chronic use of Phenytoin, a drug that belongs to the hydantoin class, a sodium channel blocker, metabolized by hepatic CYP2C9/10, it is one of the first-choice antiepileptics for treatment/management of epilepsy. This report highlights the case of a patient who presented difficulty in walking and consequently worsened motor coordination, gingival hyperplasia and hirsutism. After investigation through laboratory and imaging tests, phenytoin intoxication was confirmed due to its chronic use and cerebellar atrophy developing gait ataxia.
References
Algahtani, H., Shirah, B., Alqahtani, A. J., & Al-Malki, A. Q. (2020). Irreversible Cerebellar Atrophy as a Complication of Short-Term Phenytoin Exposure: Clinical Improvement Following Discontinuation of the Culprit. Journal of epilepsy research, 10(2), 96–99. https://doi.org/10.14581/jer.20016
Alvarado, Á. T. et al. (2020). Estudio del índice nivel/dosis de la fenitoína en pacientes epilépticos voluntarios de Mérida. Revista Médica Clínica Las Condes, 31(2), 197-203. https://www.sciencedirect.com/science/article/pii/S0716864020300249?via%3Dihub.
Anderson, G. D., & Hakimian, S. (2018). Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy. Drugs & aging, 35(8), 687–698. https://doi.org/10.1007/s40266-018-0562-2.
BRASIL. Ministério da Saúde. Secretária de Atenção à Saúde. (2018). Portaria Conjunta nº 17, de 21 de junho, Brasília. https://bvsms.saude.gov.br/bvs/saudelegis/sas/2018/poc0017_27_06_2018.html.
Calsani, I. C. A., Lopes, D. V., & Pessina, L. L. (2007). A Influência Da Ataxia Cerebelar Progressiva Na Marcha Humana: Um Estudo De Caso. Brazilian Journal of Physical Therapy, 11(Suppl.), 18-18. UFSCar. https://portalatlanticaeditora.com.br/index.php/fisioterapiabrasil/article/download/1734/2861.
Castro, K. D. S. K., Pereira, L. B. C., & Ribeiro, B. M. (2021). Como Escrever Um Relato De Caso? Manual De Produção Científica. COIMAMA Ed. Itacaiúnas 1(1). doi.org/10.36599/itac-manproc
Colin, S. L. et al. (2019). Protocolo para monitoramento terapêutico hospitalar da fenitoína. UFSC. Ciências da Saúde. Florianópolis. https://repositorio.ufsc.br/handle/123456789/202201.
Espinosa-Jovel, C. (2020) Cannabinoides en epilepsia: eficacia clínica y aspectos farmacológicos. Neurología, Science Direct. 32. https://doi.org/10.1016/j.nrl.2020.02.005.
Ferner, R., Day, R., & Bradberry, S. M. (2022). Phenytoin and damage to the cerebellum - a systematic review of published cases. Expert opinion on drug safety, 21(7), 957–977. https://doi.org/10.1080/14740338.2022.2058487
Guirao-Bringas, P., & Díaz-Pérez, G. (2012). Atrofia cerebelosa y uso crónico de fenitoína: Revisión de la literatura y presentación de un caso clínico. Revista chilena de neuro-psiquiatría, 50(1), 42-50. http://dx.doi.org/10.4067/S0717-92272012000100005
Hakami T. (2021). Neuropharmacology of Antiseizure Drugs. Neuropsychopharmacology reports, 41(3), 336–351. https://doi.org/10.1002/npr2.12196
Hilal-Dandan, R., & Brunton, L. (2015). Manual de farmacologia e terapêutica de Goodman & Gilman. AMGH Editora.
Iorga, A., & Horowitz, B. Z. (2022). Phenytoin Toxicity. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482444/.
Leitão, A. M. M., de Gusmão, I. N. B., Cavalcante¹, J. T. N. M., Andrade, L. M. N., Isabel, M., de Alencar Cavalcante¹, M. C. F., ... & Morais, L. F. P. (2020). Análise Do Número De Internações Por Epilepsia Na População Pediátrica Por Região Do Brasil Nos últimos 10 anos. Ciencia biológica e da saúde: pesquisas básicas e avançadas 1(1) https://sseditora.com.br/wp-content/uploads/1-analise-do-numero-de-internacoes-por-epilepsia-na-populacao-pediatrica-por-regiao-do-brasil-nos-ultimos-10-anos.pdf.
Marano, M., Nicoletti, F., Pro, S., Goffredo, B. M., Cecchetti, C., Piervincenzi, E., Agolini, E., & Cocciadiferro, D. (2020). Phenytoin intoxication associated with omeprazole administration in a child with defective CYP2C9. European journal of clinical pharmacology, 76(5), 731–732. https://doi.org/10.1007/s00228-019-02821-y
Nolasco, M. N., Ferreira, W. M., & Rivero, J. R. L. (2020). Epidemiologia dos casos de internação hospitalar por epilepsia no estado do Tocantins em 2018 / Epidemiology of epilepsy cases in the state of Tocantins in 2018. Brazilian Journal of Health Review, 3(6), 17268–17280. https://doi.org/10.34119/bjhrv3n6-148
Ortega-Rosado, J. C., Puig-Lagunes, Á. A., Velazco-Cercas, E., Beltrán-Parrazal, L., Morgado-Valle, C., Pérez-Estudillo, C. A., ... & López-Meraz, M. L. (2015). Epilepsia y cerebelo. Eneurobiología, 6(11). https://eneurobiologia.uv.mx/index.php/eneurobiologia/article/view/2588/4469.
Rissardo, J. P., & Caprara, A. L. F. (2022). Phenytoin-associated movement disorder: A literature review. Tzu chi medical journal, 34(4), 409–417. https://doi.org/10.4103/tcmj.tcmj_74_22
Royer, J., Bernhardt, B. C., Larivière, S., Gleichgerrcht, E., Vorderwülbecke, B. J., Vulliémoz, S., & Bonilha, L. (2022). Epilepsy and brain network hubs. Epilepsia, 63(3), 537–550. https://doi.org/10.1111/epi.17171
Weinstein R. (2021). Writing scientific case reports for top-line journals. Journal of clinical apheresis, 36(3), 465–469. https://doi.org/10.1002/jca.21869
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Hayslla Mikaella do Couto Araújo; Bruna Brugnerotto Simonetto; Claudio Henrique Cruz Camilo de Souza; Adriana Benatti Bilheiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
